

# Emilio Portaccio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7018932/publications.pdf>

Version: 2024-02-01

125  
papers

6,540  
citations

57631

44  
h-index

74018

75  
g-index

128  
all docs

128  
docs citations

128  
times ranked

5148  
citing authors

#	ARTICLE	IF	CITATIONS
1	Decannulation and improvement of responsiveness in patients with disorders of consciousness. <i>Neuropsychological Rehabilitation</i> , 2022, 32, 520-536.	1.0	7
2	Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. <i>Multiple Sclerosis Journal</i> , 2022, 28, 132-138.	1.4	31
3	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2022, 28, 472-479.	1.4	13
4	Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course. <i>Multiple Sclerosis Journal</i> , 2022, 28, 154-159.	1.4	3
5	Effect of BDNF Val66Met polymorphism on hippocampal subfields in multiple sclerosis patients. <i>Molecular Psychiatry</i> , 2022, 27, 1010-1019.	4.1	10
6	Comparing natural history of early and late onset pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2022, , .	2.8	6
7	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	1.4	16
8	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â€™%years. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2137-2141.	1.4	3
9	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. <i>Brain</i> , 2022, 145, 2796-2805.	3.7	38
10	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. <i>Neurology</i> , 2022, 98, e1626-e1636.	1.5	7
11	Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series. <i>Multiple Sclerosis Journal</i> , 2021, 27, 198-207.	1.4	10
12	Impact of occupational complexity on cognitive decline in the oldest-old. <i>Aging and Mental Health</i> , 2021, 25, 1630-1635.	1.5	6
13	Gray matter atrophy cannot be fully explained by white matter damage in patients with MS. <i>Multiple Sclerosis Journal</i> , 2021, 27, 39-51.	1.4	21
14	Understanding the pathophysiology of cognitive changes in MS: A step forward. <i>Multiple Sclerosis Journal</i> , 2021, 27, 4-5.	1.4	1
15	Cognitive Issues in Pediatric Multiple Sclerosis. <i>Brain Sciences</i> , 2021, 11, 442.	1.1	18
16	The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 645220.	1.1	13
17	Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 414.	4.5	86
18	DMTs and Covidâ€™19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	1.7	86

#	ARTICLE	IF	CITATIONS
19	Linking structural and functional brain alterations in patients with relapsing-remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118314.	0.3	0
20	Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis. <i>Brain Sciences</i> , 2021, 11, 1444.	1.1	5
21	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. <i>Cell Reports</i> , 2021, 37, 110094.	2.9	38
22	Critical illness polyneuromyopathy: Functional impact after severe acquired brain injuries. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 574-584.	1.0	9
23	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , 2020, 143, 3013-3024.	3.7	53
24	The minimal neuropsychological assessment of MS patients (MACFIMS): normative data of the Italian population. <i>Neurological Sciences</i> , 2020, 41, 1489-1496.	0.9	3
25	Experience with rituximab therapy in a real-life sample of multiple sclerosis patients. <i>Neurological Sciences</i> , 2020, 41, 2939-2945.	0.9	8
26	EEG and Coma Recovery Scale- <sup>®</sup> Revised prediction of neurological outcome in Disorder of Consciousness patients. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 221-228.	1.0	25
27	Decannulation After a Severe Acquired Brain Injury. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, 1906-1913.	0.5	13
28	Prognostic value of post-acute EEG in severe disorders of consciousness, using American Clinical Neurophysiology Society terminology. <i>Neurophysiologie Clinique</i> , 2019, 49, 317-327.	1.0	25
29	Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors. <i>PLoS ONE</i> , 2019, 14, e0222929.	1.1	32
30	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 2157-2163.	1.8	41
31	Aging with multiple sclerosis: prevalence and profile of cognitive impairment. <i>Neurological Sciences</i> , 2019, 40, 1651-1657.	0.9	39
32	Breastfeeding and post-partum relapses in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1211-1216.	1.4	21
33	Score on Coma Recovery Scale- <sup>®</sup> Revised at admission predicts outcome at discharge in intensive rehabilitation after severe brain injury. <i>Brain Injury</i> , 2018, 32, 730-734.	0.6	39
34	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e823-e831.	1.5	102
35	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e832-e839.	1.5	74
36	Improvement on the Coma Recovery Scale- <sup>®</sup> Revised During the First Four Weeks of Hospital Stay Predicts Outcome at Discharge in Intensive Rehabilitation After Severe Brain Injury. <i>Archives of Physical Medicine and Rehabilitation</i> , 2018, 99, 914-919.	0.5	31

#	ARTICLE	IF	CITATIONS
37	Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1234-1242.	1.4	33
38	Aging process, adherence to Mediterranean diet and nutritional status in a large cohort of nonagenarians: Effects on endothelial progenitor cells. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 84-90.	1.1	37
39	Author response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , 2018, 91, 851-851.	1.5	4
40	Multiple sclerosis and cognition: synaptic failure and network dysfunction. <i>Nature Reviews Neuroscience</i> , 2018, 19, 599-609.	4.9	151
41	A decline in cognitive function should lead to a change in disease-modifying therapy “ No. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1683-1684.	1.4	5
42	The dilemma of benign multiple sclerosis: Can we predict the risk of losing the “benign status”? A 12-year follow-up study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 71-73.	0.9	6
43	Maturational Trajectory of Processing Speed Performance in Pediatric Multiple Sclerosis. <i>Developmental Neuropsychology</i> , 2017, 42, 299-308.	1.0	4
44	Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1258-1267.	1.4	209
45	Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability. <i>Frontiers in Neurology</i> , 2017, 8, 608.	1.1	19
46	Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309903.	0.9	162
47	History of multiple sclerosis in 2 successive pregnancies. <i>Neurology</i> , 2016, 87, 1360-1367.	1.5	16
48	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1741-1749.	1.4	32
49	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 799-805.	2.4	13
50	Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 628-640.	1.4	28
51	Immunomodulatory therapies delay disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1732-1740.	1.4	48
52	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. <i>BMC Neurology</i> , 2015, 15, 204.	0.8	31
53	Fertility, Pregnancy and Childbirth in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs. <i>CNS Drugs</i> , 2015, 29, 207-220.	2.7	75
54	Appraisal of Brain Connectivity in Radiologically Isolated Syndrome by Modeling Imaging Measures. <i>Journal of Neuroscience</i> , 2015, 35, 550-558.	1.7	42

#	ARTICLE	IF	CITATIONS
55	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 845-850.	0.9	66
56	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. <i>BMC Neurology</i> , 2014, 14, 171.	0.8	99
57	Causes of diplopia in the emergency department. <i>European Journal of Emergency Medicine</i> , 2014, 21, 118-124.	0.5	21
58	Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. <i>Multiple Sclerosis Journal</i> , 2014, 20, 91-98.	1.4	103
59	Posterior brain damage and cognitive impairment in pediatric multiple sclerosis. <i>Neurology</i> , 2014, 82, 1314-1321.	1.5	56
60	The Rao's Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population. <i>Neurological Sciences</i> , 2014, 35, 79-82.	0.9	31
61	Neuropsychological features in childhood and juvenile multiple sclerosis. <i>Neurology</i> , 2014, 83, 1432-1438.	1.5	227
62	Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 214-219.	1.4	51
63	Anxiety state affects information processing speed in patients with multiple sclerosis. <i>Neurological Sciences</i> , 2014, 35, 559-563.	0.9	51
64	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. <i>BMC Neurology</i> , 2014, 14, 114.	0.8	27
65	Emotional and neutral verbal memory impairment in Multiple Sclerosis. <i>Journal of the Neurological Sciences</i> , 2014, 341, 28-31.	0.3	11
66	Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient. <i>Journal of Neurology</i> , 2013, 260, 1675-1677.	1.8	23
67	Increased CD8+ T cell responses to apoptotic T cell-associated antigens in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2013, 10, 94.	3.1	22
68	Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 683-692.	1.3	17
69	Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1044-1048.	0.6	4
70	Prevalence of patient-reported dysphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire). <i>Journal of the Neurological Sciences</i> , 2013, 331, 94-97.	0.3	53
71	Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. <i>Neurology</i> , 2013, 80, 2090-2094.	1.5	63
72	Cognitive reserve and cortical atrophy in multiple sclerosis. <i>Neurology</i> , 2013, 80, 1728-1733.	1.5	113

#	ARTICLE	IF	CITATIONS
73	Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing/remitting multiple sclerosis: a prospective, non-randomized pilot study. <i>European Journal of Neurology</i> , 2013, 20, 986-990.	1.7	46
74	No association between chronic cerebrospinal venous insufficiency and pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1791-1796.	1.4	19
75	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 329-334.	1.4	77
76	Truly benign multiple sclerosis is rare: let's stop fooling ourselves-Yes. <i>Multiple Sclerosis Journal</i> , 2012, 18, 13-14.	1.4	20
77	Withdrawal of fingolimod treatment for relapsing/remitting multiple sclerosis: report of six cases. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1636-1639.	1.4	50
78	Management options in multiple sclerosis-associated fatigue. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 207-216.	0.9	46
79	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. <i>BMC Neurology</i> , 2012, 12, 124.	0.8	82
80	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. <i>BMC Neurology</i> , 2012, 12, 165.	0.8	78
81	Riproducibilit� del punteggio EDSS calcolato con un nuovo software dedicato rispetto al metodo tradizionale in uso. <i>Quaderni Italiani Di Psichiatria</i> , 2012, 31, 26-31.	0.1	0
82	Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study. <i>PLoS ONE</i> , 2012, 7, e35843.	1.1	82
83	Relevance of Brain Lesion Location to Cognition in Relapsing Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e44826.	1.1	78
84	Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. <i>Core Evidence</i> , 2011, 6, 13.	4.7	11
85	Multiple sclerosis in Italy: cost-of-illness study. <i>Neurological Sciences</i> , 2011, 32, 787-794.	0.9	33
86	Cognitive impairment and event-related potentials in paediatric multiple sclerosis: 2-year study. <i>Neurological Sciences</i> , 2011, 32, 1043-1046.	0.9	13
87	Is there a future for donepezil therapy in the treatment of multiple sclerosis-related cognitive impairment?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1243-1246.	1.4	4
88	Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis. <i>PLoS ONE</i> , 2011, 6, e19452.	1.1	74
89	Psychosocial issue in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 467-470.	0.9	42
90	Cognitive rehabilitation in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 275-278.	0.9	13

#	ARTICLE	IF	CITATIONS
91	Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2010, 16, 62-67.	1.4	144
92	Cortical functional reorganization and its relationship with brain structural damage in patients with benign multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1326-1334.	1.4	30
93	Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1474-1482.	1.4	157
94	Reliability, practice effects, and change indices for Rao's brief repeatable battery. <i>Multiple Sclerosis Journal</i> , 2010, 16, 611-617.	1.4	52
95	Impact of cognitive impairment on coping strategies in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 127-130.	0.6	47
96	The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 620-626.	1.4	56
97	Switching to Second-Line Therapies in Interferon-Beta-Treated Relapsing-Remitting Multiple Sclerosis Patients. <i>European Neurology</i> , 2009, 61, 177-182.	0.6	12
98	APOE- $\epsilon$ 4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1489-1494.	1.4	21
99	The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 472-478.	1.4	31
100	Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis. <i>Neurological Sciences</i> , 2009, 30, 15-20.	0.9	110
101	ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2009, 120, 439-441.	1.0	11
102	Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. <i>Journal of the Neurological Sciences</i> , 2009, 284, 223.	0.3	4
103	Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , 2009, 286, 109-113.	0.3	23
104	Improving Compliance with Interferon- $\beta$ Therapy in Patients with Multiple Sclerosis. <i>CNS Drugs</i> , 2009, 23, 453-462.	2.7	33
105	"Subclinical MS": follow-up of four cases. <i>European Journal of Neurology</i> , 2008, 15, 858-861.	1.7	35
106	Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety. <i>Journal of the Neurological Sciences</i> , 2008, 266, 25-30.	0.3	23
107	Cognitive changes in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1585-1596.	1.4	141
108	Long-Term Adherence to Interferon $\beta$ Therapy in Relapsing-Remitting Multiple Sclerosis. <i>European Neurology</i> , 2008, 59, 131-135.	0.6	86

#	ARTICLE	IF	CITATIONS
109	Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis. <i>Archives of Neurology</i> , 2007, 64, 1157.	4.9	203
110	Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. <i>Multiple Sclerosis Journal</i> , 2007, 13, 676-678.	1.4	24
111	Clinical outcome measures in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2007, 259, 118-122.	0.3	45
112	New natural history of interferon- $\beta$ -treated relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2007, 61, 300-306.	2.8	251
113	The Rao's Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population. <i>Multiple Sclerosis Journal</i> , 2006, 12, 787-793.	1.4	343
114	Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. <i>Multiple Sclerosis Journal</i> , 2006, 12, 281-286.	1.4	30
115	Are there protective treatments for cognitive decline in MS?. <i>Journal of the Neurological Sciences</i> , 2006, 245, 183-186.	0.3	51
116	Neocortical volume decrease in relapsing-remitting multiple sclerosis with mild cognitive impairment. <i>Journal of the Neurological Sciences</i> , 2006, 245, 195-199.	0.3	30
117	Multiple sclerosis-related cognitive changes: A review of cross-sectional and longitudinal studies. <i>Journal of the Neurological Sciences</i> , 2006, 245, 41-46.	0.3	465
118	Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon- $\beta$ . <i>Journal of the Neurological Sciences</i> , 2006, 244, 97-102.	0.3	40
119	Benign multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, 1054-1059.	1.8	147
120	Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. <i>Brain</i> , 2006, 129, 2008-2016.	3.7	75
121	Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 757-759.	0.9	55
122	Clinical correlations of CSF single IgG bands. <i>Journal of Neurology</i> , 2005, 252, 1274-1275.	1.8	11
123	Interobserver agreement on Poser's and the new McDonald's diagnostic criteria for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 481-485.	1.4	16
124	Safety and tolerability of cyclophosphamide pulses in multiple sclerosis: a prospective study in a clinical cohort. <i>Multiple Sclerosis Journal</i> , 2003, 9, 446-450.	1.4	37
125	Changes in Neuropsychological Test Performance Over the Workday in Multiple Sclerosis. <i>Clinical Neuropsychologist</i> , 2003, 17, 551-560.	1.5	38